GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CNS Pharmaceuticals CNSP · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.94

+0.51%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About CNS Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

CNS Pharmaceuticals is based in Houston, Texas and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker CNSP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $15.9m. At that date it held total assets of $8.6m and shareholders' equity of $4.5m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
8 Nov 2019
Employees
8
Head office
2100 WEST LOOP SOUTH, HOUSTON, TX, 77027
Incorporated in
NV
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Ms. Faith CharlesIndependent Non-Executive Chairman of the Board$78,882
  • Mr. Rami LevinPresident, Chief Executive Officer, Director, since 2026
  • Mr. Steve O'LoughlinChief Financial Officer
  • Dr. Donald PickerChief Science Officer
  • Dr. Lynne KelleyChief Medical Officer
  • Dr. Bettina CockroftIndependent Director$52,875
  • Mr. Carl EvansIndependent Director$15,290
  • Dr. Jerzy GumulkaIndependent Director$50,925
  • Mr. Jeffry KeyesIndependent Director$59,750
  • Ms. Amy MaheryIndependent Director$46,828

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Preclinical stage pharmaceutical company focused on anticancer drug candidates for brain and CNS tumors.
  • Headquartered in Houston, Texas with a small team of 3 full-time employees.
  • Lead drug candidate Berubicin is an anthracycline targeting glioblastoma treatment.

Weaknesses

  • Limited employee count of 3 full-time staff indicates minimal operational capacity.
  • Preclinical stage development suggests early research phase without approved products.
  • IPO in 2019-11-08 indicates a relatively new public company with limited market history.

Opportunities

  • Potential for Berubicin to address unmet medical needs in glioblastoma treatment.
  • Focus on brain and CNS tumors represents a specialized market segment.
  • Pharmaceutical sector growth in oncology drug development offers expansion potential.

Threats

  • Preclinical stage development carries high risk of failure in drug development.
  • Small employee count may hinder research and development capabilities.
  • Competition in oncology drug development could limit market access.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.